KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
K Malinowska-OzdowyC FrechA SchöneggerC EckertG CazzanigaM StanullaU zur StadtA MecklenbräukerM SchusterD KneidingerA von StackelbergF LocatelliM SchrappeM A HorstmannA AttarbaschiChristoph BockG MannO A HaasR Panzer-GrümayerPublished in: Leukemia (2015)
High hyperdiploidy defines the largest genetic entity of childhood acute lymphoblastic leukemia (ALL). Despite its relatively low recurrence risk, this subgroup generates a high proportion of relapses. The cause and origin of these relapses remains obscure. We therefore explored the mutational landscape in high hyperdiploid (HD) ALL with whole-exome (n=19) and subsequent targeted deep sequencing of 60 genes in 100 relapsing and 51 non-relapsing cases. We identified multiple clones at diagnosis that were primarily defined by a variety of mutations in receptor tyrosine kinase (RTK)/Ras pathway and chromatin-modifying genes. The relapse clones consisted of reappearing as well as new mutations, and overall contained more mutations. Although RTK/Ras pathway mutations were similarly frequent between diagnosis and relapse, both intergenic and intragenic heterogeneity was essentially lost at relapse. CREBBP mutations, however, increased from initially 18-30% at relapse, then commonly co-occurred with KRAS mutations (P<0.001) and these relapses appeared primarily early (P=0.012). Our results confirm the exceptional susceptibility of HD ALL to RTK/Ras pathway and CREBBP mutations, but, more importantly, suggest that mutant KRAS and CREBBP might cooperate and equip cells with the necessary capacity to evolve into a relapse-generating clone.
Keyphrases
- acute lymphoblastic leukemia
- wild type
- tyrosine kinase
- free survival
- multiple sclerosis
- genome wide
- single cell
- gene expression
- epidermal growth factor receptor
- randomized controlled trial
- clinical trial
- induced apoptosis
- acute myeloid leukemia
- dna damage
- copy number
- allogeneic hematopoietic stem cell transplantation
- cell death
- cell proliferation
- cancer therapy
- early life
- signaling pathway
- cell cycle arrest